Previous 10 | Next 10 |
Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers ; overall response rates of 22% (including one complete response) and 67%, respectively Emergent safety profile of BT5528 suggests notable differentiation from c...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Morgan S...
Cowen launched its coverage on oncology-focused biotech Bicycle Therapeutics ( NASDAQ: BCYC ) on Wednesday, arguing that the company’s therapeutic platform of bicycle toxin conjugates (BTC) can outshine another cancer drug class called antibody-drug conjugates (ADC). ...
Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q2 GAAP EPS of -$0.90 misses by $0.04 . Revenue of $4.38M (+144.7% Y/Y) beats by $0.69M . For further details see: Bicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0....
- Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II study of BT5528 - Expansion of Genentech exclusive strategic collaboration, triggering a $10 million payment to Bicycle in Q3 - Cash and cash equival...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting data using tris-Gold complexes to ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting preclinical data from BT7480, a Bicy...
Bicycle Therapeutics ( NASDAQ: BCYC ) will get $10M from Genentech as the Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) unit exercised its second option to begin a new program under a collaboration to discover, develop and sell novel immuno-oncology therapies. The two ...
Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( ...
BCYC was founded by a Nobel Prize winner. Hopefully, that will not be its only claim to fame. However, convincing proof of concept is another year away. Bicycle Therapeutics plc ( BCYC ) is co-founded by Nobel Prize winning molecular biologist Dr. Greg Winter, who is...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of four abstracts for poster presentation at the European So...
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...